Check out the @WuXi_AppTec “BOLD: Innovation That Matters” event happening today.
Hear from our CSO @EddineSaiah on how we’re expanding the definition of druggability by unlocking the power of targeted protein #deubiquination.
Tune in: https://t.co/3qCDKwhNmT
#TakingBOLDAction
Why is our collaboration with @VertexPharma the perfect match? Our CEO, Tony Kingsley, explains:
“We bring DUB biology and chemistry, they bring the target disease and disease expertise.”
Check out the full article by @Nicole_DeFeudis of @endpts here! 👇
https://t.co/ABUxb3Gfoi
We’re thrilled to announce our collaboration with @VertexPharma to discover & develop #TPS (targeted protein stabilization) therapeutics.
Learn how we’re exploring the potential of targeted protein #deubiquitination for patients in need of breakthroughs: https://t.co/mDikkHcsXs
Our COO and co-founder, Kevin Sprott, is thrilled to speak in a panel discussion at the #wellsfargo 2023 Targeted Protein Degradation (#TPD) Virtual Summit tomorrow (2p EST), as we establish a new paradigm for restoring protein function. https://t.co/k95kbmQaU6
Tony Kingsley is taking charge at Stablix, a biotech startup out of Versant that announced a $63 million launch raise just a couple of months before the biotech exec found the exit at Scholar Rock.
https://t.co/3d5FskEsXF
Versant-backed Stablix has launched to use heterobifunctional moecules to tap into the ubiquitin-proteasome system--but they're not crunching down proteins, they're trying to restore their function. My story: https://t.co/nBvWl1WGcp
We are excited to announce our Series A launch to pioneer this new therapeutic white space and address a number of devastating diseases! #targetedproteinstabilization#stablix#TPS
https://t.co/RieJDUk2Tp